Celsius Holdings (CELH)
NASDAQConsumer StaplesBeverages - Non-alcoholicSnapshot 2026-11-05
$30.04-2.31%
Close 2026-11-05 · 1-day change
NASDAQConsumer StaplesBeverages - Non-alcoholicSnapshot 2026-11-05
Research Workspace
Put CELH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Staples is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Gross margin stays at or above 50% in FY26: Comparison needs review.
View ThesisRevenue is growing steadily — about 49% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens weak on earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 60% in its worst 12-month stretch.
View RiskCelsius's portfolio expansion has to keep compounding to justify the price. Revenue grew 16.8% last quarter and the company beat estimates. The stock trades at 22 times earnings versus a 16 times peer median. This premium is a discount to its own recent history. The gross margin pillar is under pressure, though the comparison is unverified. The thesis comparison is not yet verified. Peer multiples imply a price about 12% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-05. CELH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 24 analysts currently covering CELH (as of Nov 2026).
Based on 12 Wall Street analysts offering 12-month price targets for CELH in the last 4 months.
Continue this research
Compare CELH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CELH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Soft Drinks & Non-alcoholic Beverages — fair value, gap to price, and forward P/E.
Compare the value case
Put CELH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand revenue growth through portfolio integration and market expansion
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-05. EPS is implied from price ÷ P/E. Not investment advice.
Current $30.04
The last 12 months of price, then the range of analyst 12-month targets from today’s $30.04.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Concrete international growth target supports expansion thesis.
Advances: Expand revenue growth through portfolio integration and market expansion
Record revenue and Alani Nu growth confirm expansion thesis.
Advances: Expand revenue growth through portfolio integration and market expansion
Q3 beat validates Alani Nu offsetting core brand weakness.
Lawsuit challenges health claims, posing legal and reputational risk.
Threatens: Improve gross margin and operational efficiency
Price target cut signals margin concerns, challenging efficiency goals.
Advances: Execute disciplined capital allocation including share repurchases
CEO share purchase signals confidence in capital allocation strategy.
Expand revenue growth through portfolio integration and market expansion
Conference notes confirm portfolio gains but highlight near-term strain.
Downgrade indicates potential headwinds to revenue growth.
